300813 TAILIN
- 17.92
- -0.21-1.16%
TAILIN News
Express News | Tailin has recently obtained 6 patent certificates.
Express News | Tailin Biotech: Recently obtained 9 patent certificates and 4 software copyright certificates
Tailin Biotech (300813.SZ) plans to pay 1 yuan for 10 shares to be deducted from interest on May 27
Tailin Biotech (300813.SZ) announced that the company's 2023 equity distribution plan: every 10 shares to all shareholders...
Tailin Biotech: The conversion price was adjusted from 16.5 yuan/share to 16.4 yuan/share
Zhejiang Tailin Biotechnology Co., Ltd. announced that the conversion price of “Tailin Biotech” was adjusted from 16.5 yuan/share to 16.4 yuan/share. The effective date of the conversion price adjustment is May 27, 2024.
The concept of cellular immunotherapy fluctuated and declined. Jimin Medical and Nanhua Biotech fell to a standstill, Tailin Biotech fell by more than 8%, and Nanjing Xinbai and Sihuan Biotech followed suit.
The concept of cellular immunotherapy fluctuated and declined. Jimin Medical and Nanhua Biotech fell to a standstill, Tailin Biotech fell by more than 8%, and Nanjing Xinbai and Sihuan Biotech followed suit.
Express News | Tailin Biotech: There have been no major changes in the business situation and internal and external business environment
Tailin Biotech (300813.SZ): The subsidiary has no products in the manufacture of bio-based materials or synthetic materials
Gelonghui, May 9丨Tailin Biology (300813.SZ) said on the investor interactive platform that its subsidiary Tailin Medical Devices currently has no products in the manufacture of bio-based materials or synthetic materials.
Tailin Biotech (300813.SZ): The company has no medical equipment related to autologous stem cell regeneration insulin transplantation
Gelonghui, May 9丨Tailin Biotech (300813.SZ) said on the investor interactive platform that the company has no medical equipment related to autologous stem cell regeneration insulin transplantation.
China Securities Convertible Bonds Index closed up 0.8%, Kaineng Bonds rose more than 19%, Tailin and Knapp Bonds rose more than 11%; Fenggong Convertible fell by more than 17%; and Wei24 Convertible Bonds fell nearly 10%.
China Securities Convertible Bonds Index closed up 0.8%, Kaineng Bonds rose more than 19%, Tailin and Knapp Bonds rose more than 11%; Fenggong Convertible fell by more than 17%; and Wei24 Convertible Bonds fell nearly 10%.
Express News | Cellular immunity concepts are repeatedly active, and Tailin BioShock rises and stops
The China Securities Convertible Index opened down 0.02%. Among them, Shang Rong Convertible, Polaroid, Hangxin Convertible, Baichuan Transfer 2, and Jin Dan Convertible had the highest declines, falling 3.09%, 1.82%, 1.64%, 1.26%, and 1.1%, respectively.
The China Securities Convertible Index opened down 0.02%. Among them, Shang Rong Convertible, Polaroid, Hangxin Convertible, Baichuan Transfer 2, and Jin Dan Convertible had the highest declines, falling 3.09%, 1.82%, 1.64%, 1.26%, and 1.1%, respectively. In terms of growth, Kaineng Convertible Bonds, Tailin Convertible Bonds, Nootai Convertible Bonds, Mingdian Convertible Bonds, and Mingdian Transfer 02 had the highest gains, rising 13.74%, 10.38%, 1.15%, 1.1%, and 1.07%, respectively.
Tailin Biology (300813.SZ): Currently, there is no direct layout in the direction of synthetic biology
On May 7, Gelonghui | Tailin Biotech (300813.SZ) said on the investor interactive platform that the company currently has no direct layout in the direction of synthetic biology.
Express News | Tailin Medical Engineering Experimental Center obtained CNAS laboratory accreditation certificate
Tailin Biotech (300813.SZ): 2023 net profit pre-reduced by 66.12%-77.41%
Gelonghui, January 30, 丨 Tailin Biotech (300813.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 18 million yuan to 27 million yuan, down 77.41%-66.12% from the same period last year; net profit profit after deducting non-recurring profit and loss was 11 million yuan to 16.5 million yuan, down 84.87%-77.31% from the same period last year. The main reasons why the company's net profit attributable to shareholders of listed companies declined in the same direction during the reporting period compared to the previous year: 1. During the reporting period, the inspection period required by some customers was extended
Express News | Tailin Biotech and others set up new medical technology companies, including remote health management services
Tailin Biotech (300813.SZ) subsidiary plans to invest 10 million yuan in Hongzhong Baide to cultivate new business growth points
Tailin Biotech (300813.SZ) announced that Zhejiang Tailin Life Science Co., Ltd., a wholly-owned subsidiary of the company (abbreviation “...
Tailin Biotech (300813.SZ): Proposes to establish a joint venture to carry out business related to cell testing, cell drugs, intelligent microbial testing, etc.
Gelonghui, January 2, 丨 Tailin Biology (300813.SZ) announced that on December 28, 2023, Zhejiang Tailin Biotechnology Co., Ltd. and Keyida Biotechnology (Hangzhou) Co., Ltd. (“Keyida”), a partnership (limited partnership) of Kezhda Enterprise Management Consulting (Hangzhou) Co., Ltd. (“Kezhda”) signed an “Agreement on the Establishment of a Joint Venture” and set up a joint venture to carry out cell testing, cell drugs, intelligent microbiological testing and other related businesses. The registered capital of the joint venture is proposed to be RMB 30 million, of which the company invested 15.3 million yuan, accounting for the share
Gaode Investment, the majority shareholder of Tailin Biotech (300813.SZ), completed a reduction in holdings and reduced its holdings by a total of 521,900 shares
Tailin Biotech (300813.SZ) announced that the company's shareholder holding 5% or more of Gaode's investment holdings reduction plan has been implemented...
Tailin Biotech (300813.SZ): Won the overall asset transfer project involving the former Fusheng Electric Appliance Branch 2 with 136 million yuan
Gelonghui on December 19丨Tailin Biotech (300813.SZ) announced that on December 19, 2023, Zhejiang Tailin Medical Engineering Co., Ltd. (“Tailin Medical Engineering”), a wholly-owned subsidiary of the company, participated in the auction for the “Total Transfer of Assets Related to the Former Fusheng Electric Appliance Branch 2” project through a listing by Zhejiang Property Exchange Co., Ltd. The company won the “Total Transfer of Assets Involved in the Former Fusheng Electric Appliance Branch 2” project at a price of RMB 136.1 million, and received the “Notice of Signing” issued by Zhejiang Property Exchange Limited。 Tailin Medical Engineering will be with Hangzhou Fu in the future
Tailin Medical Engineering, a subsidiary of Tailin Biotech (300813.SZ), plans to participate in the auction for a plant in Hangzhou to implement a fund-raising project
Tailin Biology (300813.SZ) announced that Zhejiang Tailin Medical Engineering Co., Ltd., a wholly-owned subsidiary of the company (abbreviated as “...
Analysis
Price Target
No Data
